3-amino-6-(4-(tert-butoxycarbonyl)piperazin-1-yl)pyrazine-2-carboxylic acid | 785051-33-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 3-amino-6-(4-(tert-butoxycarbonyl)piperazin-1-yl)pyrazine-2-carboxylic acid
• 英文别名: 3-amino-6-[4-[(2-methylpropan-2-yl)oxycarbonyl]piperazin-1-yl]pyrazine-2-carboxylic acid
• CAS: 785051-33-4
• 化学式: C₁₄H₂₁N₅O₄
• 分子量: 323.352
• InChiKey: YYMFKKZGRLSMKQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  122
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  3-amino-6-(4-(tert-butoxycarbonyl)piperazin-1-yl)pyrazine-2-carboxylic acid 在 N-羟基-7-氮杂苯并三氮唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 18.25h， 生成
  参考文献：
  名称：

  [EN] AMINO-PYRAZINECARBOXAMIDE COMPOUNDS, CONJUGATES, AND USES THEREOF
  [FR] COMPOSÉS D'AMINO-PYRAZINECARBOXAMIDE, CONJUGUÉS ET LEURS UTILISATIONS

  摘要：

  本文披露了用于治疗疾病如癌症的化合物的氨基吡嗪羧酰胺化合物（I）的结构式、结合物和药物组合物。所披露的化合物在治疗癌症和纤维化以及调节TGFpR2等方面具有用途。此外，本文还描述了与抗体构造物结合的化合物。

  公开号：

  WO2019227059A1
• 作为产物：
  描述：

  3-amino-6-bromo-N-methylpyrazine-2-carboxamide 在 sodium hydroxide 、 甲酸 作用下， 以 甲醇 、 乙二醇甲醚 、 乙酸酐 为溶剂， 生成 3-amino-6-(4-(tert-butoxycarbonyl)piperazin-1-yl)pyrazine-2-carboxylic acid
  参考文献：
  名称：

  First Synthesis of Piperazine-derived [1,2,4]Triazolo[1,5-a]pyrazine as an Adenosine A2A Receptor Antagonist

  摘要：

  Synthesis of piperazine-derived 2-furan-2-yl-[1,2,4]triazolo[1,5-a] pyrazines was achieved using methyl 3-amino-2-pyrazinecarboxylate. Introduction of the piperazine to the pyrazine template was achieved through a pteridin-4-one intermediate (7). Cyclization of the [1,2,4]triazolo[1,5-a]pyrazine ring was accomplished by amination of pyrazine (8) followed by condensation with 2-furaldehyde. Curtius rearrangement installed the amine to afford template (11). As one example of derivatizing 11, 6N-(4-(2,4,6-trifluorobenzyl)piperazin-1-yl)-2-(furan-2-yl)-[1,2,4]triazolo-[1,5-a]pyrazin-8-amine (12) showed moderate adenosine A(2a) receptor binding affinity and selectivity over the A, receptor.

  DOI：

  10.3987/com-05-10493

文献信息

• [EN] TRIAZOLOPYRAZINES AND METHODS OF MAKING AND USING THE SAME<br/>[FR] TRIAZOLOPYRAZINES ET PROCEDES DE PREPARATION ET D'UTILISATION CE CELLES-CI
  申请人：BIOGEN IDEC INC

  公开号：WO2004092177A1

  公开（公告）日：2004-10-28

  The invention is based on the discovery that compounds of formula (I) possess unexpectedly high affinity for the A2a adenosine receptor, and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including Parkinson's disease. In one embodiment, the invention features a compound of formula I (See formula on paper copy)

  这项发明基于发现，式(I)化合物具有对A2a腺苷受体具有意外高亲和力，并可用作其拮抗剂，用于预防和/或治疗包括帕金森病在内的多种疾病。在一个实施例中，该发明涉及一种式I的化合物（请参见纸质副本上的式）。
• [EN] COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE<br/>[FR] COMPOSÉS UTILES COMME INHIBITEURS DE L'ATR KINASE
  申请人：VERTEX PHARMA

  公开号：WO2010054398A1

  公开（公告）日：2010-05-14

  The present disclosure relates to pyrazine compounds of formula (I) wherein L, n, R1, and R2 are as described in the specification. These compounds are useful as inhibitors of ATR protein kinase. The disclosure also relates to pharmaceutically acceptable compositions comprising the compounds of the disclosure; methods of treating of various diseases, disorders, and conditions using the compounds of the disclosure; processes for preparing the compounds of the disclosure; intermediates for the preparation of the compounds of the disclosure; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors.

  本公开涉及式(I)的吡嗪化合物，其中L、n、R1和R2如规范中所述。这些化合物可用作ATR蛋白激酶的抑制剂。本公开还涉及包含本公开的化合物的药用组合物；使用本公开的化合物治疗各种疾病、疾病和病况的方法；制备本公开的化合物的方法；制备本公开的化合物的中间体；以及在体外应用中使用这些化合物的方法，例如在生物和病理现象中研究激酶、介导这些激酶的细胞内信号转导途径的研究，以及新的激酶抑制剂的比较评估。
• [EN] TGFBETAR2 INHIBITOR-LRRC15 ANTIBODY CONJUGATES AND USES THEREOF<br/>[FR] CONJUGUÉS INHIBITEUR DE TGFBETAR2-ANTICORPS ANTI-LRRC15 ET LEURS UTILISATIONS
  申请人：SILVERBACK THERAPEUTICS INC

  公开号：WO2021102332A1

  公开（公告）日：2021-05-27

  Conjugates comprising a TGFβR2 inhibitor and an anti-LRRC15 antibody, compositions comprising the conjugates, and use of the conjugates in the treatment of disease, such as fibrosis and cancer, are disclosed herein. Also disclosed herein are anti-LRRC15 antibodies, including humanized anti-LRRC15 antibodies.

  本文披露了包括TGFβR2抑制剂和抗LRRC15抗体在内的共轭物，包括这些共轭物的组合物，以及在治疗疾病（如纤维化和癌症）中使用这些共轭物的方法。本文还披露了抗LRRC15抗体，包括人源化的抗LRRC15抗体。
• Triazolopyrazines and methods of making and using the same
  申请人：Dowling E James

  公开号：US20070010520A1

  公开（公告）日：2007-01-11

  The invention is based on the discovery that compounds of formula (I) possess unexpectedly high affinity for the A2a adenosine receptor, and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including Parkinson's disease. In one embodiment, the invention features a compound of formula I (See formula on paper copy)

  该发明基于发现，式(I)化合物具有意外的高亲和力，可作为A2a腺苷受体的拮抗剂，用于预防和/或治疗包括帕金森病在内的许多疾病。在一种实施方式中，该发明涉及式(I)化合物（见纸质复印件上的式子）。
• COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE
  申请人：Charrier Jean-Damien

  公开号：US20120040020A1

  公开（公告）日：2012-02-16

  The present disclosure relates to pyrazine compounds of formula I: wherein L, n, R 1 , and R 2 are as described in the specification. These compounds are useful as inhibitors of ATR protein kinase. The disclosure also relates to pharmaceutically acceptable compositions comprising the compounds of the disclosure; methods of treating of various diseases, disorders, and conditions using the compounds of the disclosure; processes for preparing the compounds of the disclosure; intermediates for the preparation of the compounds of the disclosure; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors.

  本公开涉及式I的吡嗪化合物：其中L、n、R1和R2如规范所述。这些化合物可用作ATR蛋白激酶的抑制剂。本公开还涉及包含本公开化合物的药学上可接受的组合物；使用本公开化合物治疗各种疾病、障碍和病况的方法；制备本公开化合物的过程；制备本公开化合物的中间体；以及在体外应用中使用这些化合物的方法，例如研究生物和病理现象中的激酶、这些激酶介导的细胞内信号传导途径的研究以及新的激酶抑制剂的比较评估。